Hemoglobin based oxygen carriers (HBOC) have been primarily studied for blood loss treatment. More recently infusions of HBOC in euvolemic subjects have been proposed for a wide variety of potential therapies in which increased tissue oxygenation would be beneficial. However, compared to the exchange transfusion models to study blood loss, less is known about HBOC oxygen delivery and vasoacitvity when infused in euvolemic subjects. We hypothesized that HBOC (polymerized bovine hemoglobin, PBvHb) infusion creating hypervolemia would increase oxygen delivery to tissues during acute global hypoxia. Vascular oxygen content and hemodynamics were determined after euvolemic rats were infused with 3 ml of either lactated Ringer's or PBvHb solution (13 g/dl, 1.3g/kg) during acute hypoxia (FIO 2 = 10%, 4 h) or normoxia (FIO 2 = 21%) exposure. Our data demonstrated that compared to Ringer's infused animals, in hypoxia and normoxia, PBvHb treatment improved oxygen content, but raised mean arterial pressure, lowered stroke volume, heart rate, and cardiac index, which resulted in a net reduction in blood flow and oxygen delivery to the tissues. The PBvHb vasoactive effect was similar in magnitude and direction as to Ringer's infused animals treated with a nitric oxide synthase inhibitor N-L-Arginine, suggesting the PBvHb effect is mediated via nitric oxide scavenging. We conclude that infusion of PBvHb is not likely to be useful in treating global hypoxia under these conditions. Running Head: PBvHb decreases oxygen delivery.
Introduction
Hemoglobin based oxygen carriers (HBOCs) were originally designed to improve oxygen carrying capacity and blood volume in patients suffering from acute blood loss (15, 22) . HBOCs have the attractive features of universal compatibility, long storage life, and reduction of disease transmission (15) . A wide variety of other potential therapies have recently been proposed for HBOCs such as adjunct therapy during radiation and chemotherapy (19); management of pedicled flaps (18) ; reducing infarct volume as a result of focal cerebral ischemia (16); and scavenging nitric oxide (NO) (19) .
HBOCs that are of clinical interest currently constitute several types, based on the chemical modification of the hemoglobin molecules to provide longer circulation times, optimal oxygen affinity, and decrease negative side effects. These HBOC types have been reviewed recently by Winslow (26) , and are categorized into cross-linked, polymerized, and conjugated hemoglobin. Cell-free hemoglobin has long been associated with hypertension when infused (26) . Almost all polymerized hemoglobin variants induced variable degrees of vasoconstriction (9, 15, 20) . Although the cause is still debated, most HBOCs vasoconstrictive properties likely stem from NO scavenging (17, 23) . In contrast, Tsai et al. (22) demonstrated that polyethylene-glycol-decorated polymerized Hb had similar NO affinity as other polymerized Hb derivatives, but did not produce vasoconstriction. Thus, this supports the alternative theories that vasoconstriction may be a result of supra-physiological oxygenation of tissues surrounding blood vessels, dependent on the molecular volume of the oxygen binding sites on HBOCs (26) , or due to an oncotic volume expansion effect (14).
HBOC therapies have been primarily studied for blood loss treatment (7, 12, 15, 24) , and studies investigating HBOC as a means for enhanced oxygen therapy, other than for blood loss treatment, are few. (16, 18) . Unfortunately, these studies either focused on hemodynamics or on oxygen binding characteristics of HBOC, but failed to comprehensively provide data on the influence of HBOC-induced hemodynamic changes on oxygen delivery per se. HBOC infusion in euvolemic individuals would likely occur during radiation and chemotherapy therapy, pedicled flap treatment, and cerebral ischemia, to enhance tissue oxygen delivery in such conditions. We hypothesized that administration of a gluteraldehyde-polymerized bovine hemoglobin, PBvHb, to euvolemic animals during acute global hypoxia would increase oxygen carrying capacity of blood and oxygen delivery to tissues, despite the possibility of PBvHb-induced vasoconstriction and other hemodynamic changes, such as reduced cardiac output. PBvHb was chosen for this study as this HBOC has been approved for veterinary use in the United States and South Africa, and for limited use in humans in South Africa.
Our primary goal was to determine the oxygen delivery and systemic and pulmonary hemodynamic effects after a 3 ml infusion of PBvHb during acute hypoxia as compared to normoxia in a conscious rat model of global hypoxia. Therefore, studies were designed to measure oxygen content, blood gases, and pulmonary and systemic hemodynamics, in awake, conscious rats exposed to either 21% or 10% oxygen.
Secondarily, the study was designed to determine the potential role of NO in PBvHbinduced vasoactivity.
METHODS

Animals
Male Sprague-Dawley rats (280-350 g and 10-12 weeks of age) were obtained from a commercial vendor (Charles River) and housed in the University of Colorado Health Sciences Center's Center for Laboratory Animal Care (elevation = 5,280 ft).
Animals were allowed ad libitum access to food and water and kept on a 12 hr day-night cycle. All experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee at University of Colorado Health Sciences Center.
Instrumentation
Rats were allowed to acclimate to Denver altitude (5,280 ft; 1690 m; P B~ 630 mm Hg) for at least seven days prior to instrumentation. Forty-eight hours prior to surgery, rats were provided water supplemented with acetaminophen/codeine (0.5 mg/ml and 0.05 mg/ml, respectively) for postoperative analgesia. The animals were weighed and hematocrits were determined. Rats were anesthetized with a mixture of ketamine: Rompon (xylazine) (75 mg/kg: 6 mg/kg I.P.). Under aseptic conditions, the left carotid artery was cannulated with a PE-50 (0.58 mm ID; Becton Dickinson) catheter. A PV-1 (0.28 mm ID, Becton Dickinson) catheter with a shallow bend at its tip was inserted into the right ventricle via the right jugular vein and guided into the main pulmonary artery.
Pressure tracings confirmed placement in the pulmonary artery. Next, two PE-50 (0.58 mm ID, Becton Dickinson) catheters were placed in the superior vena cava via the right jugular vein for venous blood collection and to obtain cardiac output values. All catheters were flushed with heparinized saline, tied off, tunneled subcutaneously to the dorsal neck region, and exteriorized at the back of the neck. Animals were allowed at least 48 h to recover prior to any treatments. Animals demonstrating signs of infection, diarrhea, or distress were excluded from study.
Estimation of Blood Clearance Rate and physical characteristics of PBvHb.
It has previously been suggested that the PBvHb plasma concentration half-life are species and dose dependent (16, 13) . Therefore, the PBvHb clearance rate was estimated in male Sprague-Dawley rats, (n = 4) infused with 1.3 g/kg PBvHb. Arterial blood was collected hourly for 8 h post-infusion and plasma PBvHb concentrations were 6 plotted against time to estimate the PBvHb clearance rate in the rat. It was determined that the concentration was reduced by about half at ~5 ± 1 h and undetectable in the blood stream by co-oximetry 24 h after infusion (data not shown). Therefore, in the present study, PBvHb effects were measured at 2 and 4 hrs, followed by effects of NOS inhibition at 4.5 h post-infusion. The physical characteristics of PBvHb "Oxyglobin " are shown in table 1.
Model and Experimental Design
Animals were randomly assigned into one of four groups, each with a sample size of 10 animals (n = 10) unless otherwise specified: 
Hemodynamic Measurements
Rats were placed in a custom designed small, rectangular, plexiglas chambers with a portal through which catheters could be passed. Catheters were flushed with heparinized saline and then connected to fluid filled pressure transducers. Animals were exposed to normoxia and hypoxia by flushing the chamber with appropriate gases. Once breathing hypoxic gas, hypoxic animals were not re-exposed to room air. Then, blood pressures, pulmonary artery blood pressures, heart rates, and cardiac outputs of normoxic and hypoxic animals were collected prior to Ringer's or PBvHb treatment ( Figure 1 ).
All animals then underwent a 30 min (10 min per 1 ml) infusion of either Ringer's or PBvHb (3 ml/kg, 1.3 g/kg) through a venous catheter. Two and four hours following infusion, hemodynamic variables were measured along with blood gas variables (see below). Then animals were treated with 5 mg/kg of the nitric oxide synthase (NOS) inhibitor nitro-L-arginine (NLA), (Sigma Aldrich, #N10403) administered via a jugular catheter. Hemodynamics were measured 30 min post NLA infusion. Cardiac output was measured using Cardiogreen (Sigma Aldrich cat #I2633) with the dye-dilution method.
Between data collection points, the rats were monitored for any signs of distress but otherwise left undisturbed. Animals were euthanized with an overdose of sodium pentobarbital (100 mg/kg) via a jugular catheter following final measurements.
Blood Gas and Co-Oximetry Measurements for Whole Blood and Plasma
Blood samples were collected immediately after hemodynamic measurements had been obtained at each time point ( Figure 1 ). Arterial (0.2 mL) and venous (0.2 mL) blood was withdrawn via carotid and venous catheters, respectively into blood gas syringes and analyzed (ABL5, Radiometer, Copenhagen and co-oximetry via OSM3, Radiometer, Copenhagen) with algorithms specific to rat and bovine hemoglobin.
Plasma Phase Co-Oximetry. Heparinized microhematocrit capillary tubes (100 µl;
Fisherbrand, #22362566) were immediately filled from each 1 ml blood gas syringe (see above), sealed from room air with a removable cap (Kendall Healthcare, #8889212000), and spun on a capillary centrifuge to separate cell and plasma fractions. The plasma portion of the capillary tube was aspirated into the co-oximeter. Measurements were excluded if any portion of the cell fraction was inadvertently aspirated into the analyzer.
Care was taken to avoid exposing blood samples to room air.
Calculation for Oxygen Delivery, Consumption and Extraction
Oxygen delivery (DO 2 ), consumption (VO 2 ), and extraction ratio (ERO 2 ) were calculated for hemoglobin in whole blood and PBvHb in the plasma phase (no measurable endogenous hemoglobin was present in the plasma) with the mathematical calculations: 
RESULTS
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Total Hemoglobin and Methemoglobin Normoxia. As expected, total Hb concentration in whole blood was lower after a 3 ml infusion of Ringer's solution due to dilution (p < 0.01, Table 2 ). On the other hand, adding 3 ml PBvHb increased the total Hb concentration approximately 10% (p < 0.02, Table 1 ), due to the presence of PBvHb in the plasma (~ 2 g/dL, Table 2 ). An elevation of methemoglobin concentration accompanied the rise in total Hb concentration in whole blood and plasma (p < 0.04, Table 1 ). Remarkably, the methemoglobin concentration in plasma increased ~ 6 fold between 2 and 4 h in PBvHb treated animals (p = 0.03, 2h vs. 4 h, Table 2 ).
Hypoxia. Hypoxia (4 h) per se had no effect on either total or plasma Hb concentration. However, total methemoglobin concentration (p < 0.001, Table 1 ) was lower during hypoxia as compared to normoxia. This observation held true for the plasma methemoglobin concentration (p = 0.04) of PBvHb treated animals as well ( Table 2) .
Although plasma methemoglobin concentration increased in PBvHb treated animals between 2 and 4 h during normoxia, no change between these time points was noted during hypoxia. (Table 2 ).
Blood Gases
Arterial PO 2 , PCO 2 , and pH. Neither Ringer's nor PBvHb altered PO 2 , PCO 2 , or pH during normoxia or hypoxia. However, hypoxia produced expected decreases in PO 2 and PCO 2 and increases in pH (p < 0.001, Table 2 ).
Oxygen Content and Saturation
Normoxia. Whole blood oxygen content was lower following dilution by Ringer's infusion (p = 0.01, Table 2 ). Treatment with PBvHb did not improve whole blood oxygen content, yet oxygen content was measurable in the plasma phase (~1.5 mMol, Table 2 ). Whole blood oxygen saturation was unaffected by either Ringer's or PBvHb treatment. In PBvHb treated animals, oxygen saturation of the plasma phase was lower than oxygen saturation in the whole blood (p < 0.001, Table 2 ).
Hypoxia. As expected, hypoxia decreased oxygen content and saturation in whole blood and plasma (p < 0.001, Table 2 ) prior to treatment. PBvHb treated animals had significantly greater whole blood oxygen content within 2 h of hypoxia (p = 0.005, Table 2 ).
Hemodynamics
Unless otherwise stated Ringer's infusion had no effect on hemodynamic variables in animals exposed to either normoxia or hypoxia. Table 3 ). The NLA-induced increase in pressure and resistance in Ringer's infused animals was equivalent to the elevation in MAP and TPR caused by PBvHb alone (p < 0.001, Figure 2a -b, Table 4 ).
Hypoxia. Compared to normoxia, exposure to acute hypoxia decreased MAP and TPR (p < 0.001, Figure 2a -b, Table 3 ). Treatment with PBvHb then increased MAP and TPR from untreated values by approximately the same magnitude as that observed in animals that had remained in normoxic conditions (p < 0.001, Figure 2a -b, Table 3 ). In the Ringer's infused animals, NLA increased only TPR (p = 0.01, Figure 2b , Table 4 ).
NLA treatment further increased both MAP and TPR in the PBvHb infused animals (p = 0.02, Figure 2a -b, Table 4 ).
Mean Pulmonary Artery Pressure and Total Pulmonary Resistance. Normoxia. We observed no change from untreated values in mean pulmonary artery pressures in animals treated with PBvHb, but a significant increase in total pulmonary vascular resistance was noted (p < 0.001 Figure 3a -b, Table 3 ). Treatment with NLA had no effect on mean pulmonary artery pressures in either Ringer's or PBvHb group (Figure 3a-b , Table 4 ).
However, NLA increased pulmonary vascular resistance in the Ringer's infused group by to a similar extent as that observed following PBvHb treatment (p = 0.04, Figure 3b , Table 4 ).
Hypoxia. As expected, mean pulmonary artery pressure was increased with hypoxia exposure ( Table 3 ). The initial increase in pulmonary artery pressure induced solely by hypoxia was further increased with PBvHb treatment, along with an increase in pulmonary vascular resistance (p < 0.001, Figure 3a -b, Table 3 ). The pulmonary artery pressure and pulmonary vascular resistance was increased further by NLA in the Ringer's infused animals (p = 0.03, Figure 3a -b, Table 4 ). However, NLA had no additional influence on the PBvHb -induced increase in pulmonary hemodynamics (Figure 3a-b) .
Heart Rate and Pulse Pressures. Normoxia. Infusion of Ringer's or PBvHb solution caused a brief but transient decrease in HR that was resolved by 4 h (p = 0.02 for Ringer's and p = 0.003 for PBvHb, Figure 4a , Table 3 ). However, pulse pressure decreased from untreated values after PBvHb, but not with Ringer's treatment (p < 0.001, Table 1 ). NLA decreased HR and pulse pressure only in the Ringer's infused animals (p = 0.04 for HR, Figure 4a , and p < 0.001 for pulse pressure, Table 4 ).
Hypoxia. Hypoxia caused an increased HR that was reversed by treatment with PBvHb (p = 0.04, Figure 4a , Table 3 ). Hypoxia did not alter pulse pressure in Ringer's infused animals, while pulse pressure was lowered by PBvHb treatment. (p < 0.001, Table 2 ). Treatment with NLA decreased resting HR and pulse pressure in the Ringer's infused animals (p < 0.006, Figure 4a , Table 4 ), but had no effect on the PBvHb treated animals ( Figure 4a , Table 4 ).
Cardiac Index and Stroke Volume. Normoxia. Treatment with PBvHb induced a dramatic decrease in cardiac index and stroke volume (p 0.002, Figure 4b -c, Table 3 ).
NLA decreased cardiac index and stroke volume in Ringer's infused animals (p 0.02, Figure 4b -c, Table 4 ), but did not change cardiac index and stroke volume in the PBvHbtreated group.
Hypoxia. Hypoxic stress increased cardiac index (Table 3). However, hypoxia
PBvHb treatment greatly decreased cardiac index and stroke volume, as had occurred in normoxia (p = 0.006; Figure 4b -c, Table 3 ). In Ringer's infused animals, treatment with NLA induced a decrease in cardiac index and stroke volume similar in magnitude to that observed in PBvHb treated animals (p 0.02, Figure 4b -c, Table 4 ). Interestingly, NLA further decreased cardiac index and stroke volume in the PBvHb animals (p < 0.001, Figure 4b -c, Table 4 ).
Oxygen Delivery, Consumption, and Extraction
Normoxia. Treatment with PBvHb reduced oxygen delivery and VO 2 (p < 0.001, Figure 5 , Table 5 ), but Ringer's infusion did not. Thus, the calculated extraction rate for oxygen was less with PBvHb as compared to Ringer's treatment during normoxia. The reduction in oxygen extraction from whole blood was greater than that from plasma (p < 0.001, Table 5 ).
Hypoxia. Hypoxia induced a reduction in oxygen delivery in all animals as compared to normoxia, while PBvHb treatment further decreased oxygen delivery (p < 0.001, Figure 5 , Table 5 ) during hypoxia. However, the magnitude of the PBvHb -13 induced reduction in oxygen delivery was not as great as that recorded during normoxia. Initially, exposure to hypoxia lowered VO 2 in all animals (p < 0.001, Table   5 ). However, in Ringer's infused animals VO 2 had returned to normoxic values by 4 h, while PBvHb treatment during hypoxia lowered VO 2 even below that in normoxic PBvHb animals.
In all animals, hypoxia induced a rise (~18 %) in whole blood oxygen extraction ratio over the time course of the study period (p = 0.038, untreated vs. 2 and 4 h pooled, Table 4 ). However, in PBvHb treated animals, the oxygen extraction ratio for plasma was lower during acute hypoxia than during normoxia, but doubled between 2 and 4 h time period (p = 0.02, Table 4 ).
DISCUSSION
The goal of this study was to determine if an infusion of a hemoglobin-based oxygen carrier (polymerized bovine hemoglobin) could be used to improve oxygen delivery during hypoxia in a conscious euvolemic animal; and, thus, be efficacious for use during radiation and/or chemotherapy and clinical conditions of euvolemic hypoxic stress. The data do not support the use of polymerized bovine hemoglobin for such conditions. Polymerized bovine hemoglobin therapy had a far greater negative impact on cardiac index than previously recognized in reports using anesthetized animals. Thus, although polymerized bovine hemoglobin treatment slightly improved blood oxygen content, the reduction in cardiac index resulted in a large net decrease in oxygen delivery to the tissues during both normoxia and hypoxia. As expected, nitric oxide scavenging played a significant role in the hemodynamically mediated reduction in oxygen delivery changes with polymerized bovine hemoglobin treatment. Therefore, HBOCs that severely compromise cardiac index and blood flow are not likely to be useful in resolving tissue hypoxia experienced during radiation, chemotherapy, pedicled flap and cerebral ischemia treatment; unless the hemodynamic side effects can be reduced and/or ameliorated.
The HBOC used in this study consisted of purified gluteraldehyde cross-linked polymerized bovine hemoglobin. The species differences, purity and/or specific crosslink may have contributed to some of the adverse effects seen in this rat model. For example, compared to other products, HBOC prepared from human hemoglobin crosslinked with pyridoxal-5'-phosphate followed with polyoxyethylene glycol have shown to be less vasoactive in exchange transfusion models (1, 2) .
The time course of the experiments and the infused concentration of polymerized bovine hemoglobin were selected based on estimated HBOC clearance rate (see methods) and the in situ concentration of polymerized bovine hemoglobin necessary to increase the hypoxic blood oxygen content to that of the normoxic oxygen content levels. Clearance rates in the current study are similar to those previously published for mice (16). The volume (3 ml) of polymerized bovine hemoglobin or Ringer's solution infused over a 30 min period did not cause hemodynamic changes and could be safely infused without adverse effects due to volume overload, as has been previously reported (21) . The polymerized bovine hemoglobin dose (1.3 g/kg) was 1-3 fold higher than what others have used in hypervolemic models (6, 23) . However, the goal of these previous studies (6, 23) was to study the reaction between various HBOC and nitric oxide, and not to increase oxygen content to compensate for hypoxia. Interestingly, Tsai et al. suggested that microvascular effects of HBOC may not be based on concentration, but on HBOC properties such as molecular modification, molecular volume, and oxygen affinity (23) .
In fact, data indicate that as little as 0.5 g/dL of HBOC is sufficient to scavenge most intravascular nitric oxide (23) . Therefore, the larger dose of polymerized bovine hemoglobin used in the current study to compensate for a hypoxia-induced reduction in arterial oxygen content should not have had an additional nitric oxide scavenging effect.
Blood Gas Variables
A primary goal of this study was to determine whether or not polymerized bovine hemoglobin infusion could enhance blood oxygen content sufficiently to compensate for low arterial oxygen saturation and content during acute hypoxia. As expected polymerized bovine hemoglobin infusion increased total hemoglobin and arterial oxygen concentration in whole blood by about 10% in all animals. The difference in whole blood and plasma hemoglobin oxygen saturation from the current study are in agreement of previous findings in which cross-linked polymerized bovine hemoglobin have shown altered oxygen binding characteristics (3). However, our data showed that increased total hemoglobin and oxygen content tracked together at about 10% after polymerized bovine hemoglobin infusion. This would suggest that the HBOC oxygen binding was sufficient to maintain an equal relationship between total hemoglobin and oxygen content. Thus, though polymerized bovine hemoglobin has different oxygen binding characteristics than native hemoglobin, polymerized bovine hemoglobin infusion did increase oxygen content during hypoxia sufficiently to offset the loss of oxygen content that occurred during hypoxia exposure.
HBOC Hemodynamic Effects during Normoxia
Because oxygen delivery is determined by oxygen content and cardiac output, the finding that oxygen content was improved with polymerized bovine hemoglobin but cardiac output was markedly decreased in normoxia is of importance to therapeutic considerations. This is the first study to report such a large fall in cardiac output with polymerized bovine hemoglobin infusion during normoxia. The finding that polymerized bovine hemoglobin infusion increased mean arterial pressure and total peripheral resistance in normoxic conditions is in agreement with other studies demonstrating an polymerized bovine hemoglobin-induced systemic pressor response (6, 14, 17, 23) . It is likely that greater mean arterial pressure and peripheral resistance increased ventricular afterload, decreased heart rate and stroke volume, thus impairing cardiac output (8) .
Because inhibition of nitric oxide synthase in normoxia did not cause a further rise in systemic resistance or cardiac output, it is likely that nitric oxide scavenging by polymerized bovine hemoglobin was ultimately responsible for the reduction in cardiac output. It is also possible that polymerized bovine hemoglobin had a direct effect on cardiac function by inducing cardiac lesions, though this has not been demonstrated in the rat, compared to other species (4). However, investigators (4) did not demonstrate that the heart lesions directly decreased cardiac index. Overall, it appears that during normoxia, nitric oxide scavenging by polymerized bovine hemoglobin increased left ventricular afterload, lowering cardiac index. and, thus, decreased arterial blood pressure (11, 25) . Although polymerized bovine hemoglobin treatment (and nitric oxide scavenging) during hypoxia elevated vascular resistance and blood pressure, pressures were not returned to normoxic values after polymerized bovine hemoglobin treatment. This suggests that the mechanism of hypoxia-induced systemic vasodilation in the present study was not completely nitric oxide mediated. Interestingly, treatment with nitric oxide synthase inhibitor during hypoxia further elevated blood pressure and vascular resistance in polymerized bovine hemoglobin but not Ringer's treated animals. There is no clear cause of this phenomenon and more research is necessary to elucidate this issue.
Mechanisms of Polymerized Bovine Hemoglobin-Induced Vasoconstriction
Nitric oxide scavenging by HBOC is a primary contributor to rising systemic pressure during normoxia (1, 2, 6, 14, 17, 23) and our data confirm that it also contributes significantly to polymerized bovine hemoglobin-induced elevation of pulmonary artery pressure during hypoxia in conscious animals. However polymerized bovine hemoglobininduced vasoconstriction could also be influenced by volume expansion due to elevated intravascular oncotic pressure (12) and/or an "autoregulatory" vasoconstrictive effect in which a high P 50 Hb favoring rapid oxygen unloading exposing arteriolar vessel walls to supra-normal PO 2 , triggering vasoconstriction (26) .
Oxygen Delivery, Consumption, and Extraction
Polymerized bovine hemoglobin impaired oxygen delivery during both normoxia and hypoxia. The 50% reduction in cardiac index with Polymerized bovine hemoglobin infusion accounts for the decreased oxygen delivery as discussed above. Interestingly, during both normoxia and hypoxia, Polymerized bovine hemoglobin decreased oxygen consumption significantly. This is notable, because unless aerobic metabolism is decreased, one would expect oxygen consumption to be maintained near base line values throughout the 4 h study period. Interestingly, Cabrales observed a similar response in the microvasculature in a Hamster window chamber experiment 1 h after an 80% exchange transfusion (5) . Similar to those experiments, it is hard for us to draw any conclusion as to whether or not this is a positive or negative consequence of PBvHb. Perhaps Polymerized bovine hemoglobin treatment and its vascular effects resulted in preferential diversion of blood flow from higher to lower oxygen consuming tissue, but this will require further investigation.
Oxygen extraction, a function of oxygen delivery versus oxygen consumption was greater in whole blood than for plasma during Polymerized bovine hemoglobin treatment under normoxic and hypoxic conditions. This is in agreement with previous studies of oxygen transport during Polymerized bovine hemoglobin treatment (24). During hypoxia in Ringer's infused animals, as expected, the extraction of oxygen by the tissues (as reflected by the extraction ratios) increased over the 4 h study period to compensate for decreased oxygen delivery, maintaining oxygen consumption. In contrast, with Polymerized bovine hemoglobin treatment during normoxia and hypoxia, the extraction of oxygen by the tissue did not increase sufficiently to maintain oxygen consumption.
This important observation requires further investigation to determine how Polymerized
bovine hemoglobin may reduce oxygen consumption and extraction.
Summary
In conclusion, hemodynamic and blood gas data indicate that Polymerized bovine hemoglobin infusion was ineffective as a means for increasing oxygen delivery during acute hypoxic insult. In fact, Polymerized bovine hemoglobin had a negative consequence on oxygen delivery during both normoxia and hypoxia. The primary mechanism for the negative effects of Polymerized bovine hemoglobin during isovolemic hypoxia appears to be nitric oxide scavenging with confounding effects on cardiac output, oxygen extraction, and oxygen consumption. It remains to be determined if eliminating the nitric oxide scavenging properties of Polymerized bovine hemoglobin will enable Polymerized bovine hemoglobin to become an effective oxygen carrier and oxygen deliverer under normoxic and/or hypoxic conditions. 
